Abstract:We read with interest the study by Boursier et al. titled “A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis” recently published in the Journal.[1] Boursier J. de Ledinghen V. Leroy V. Anty R. Francque S. Salmon D. et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017; 66: 1158-1165 Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar Using liver biopsy as reference in a cross-sectional study, the authors developed a stepwise algorithm for the detection of advanced liver fibrosis. This algorithm comprised of a first-line test called easy liver fibrosis test (eLIFT), followed by a second-line test of FibroMeter plus vibration controlled transient elastography (FMVCTE). When tested in a longitudinal cohort of 1,275 patients, the eLIFT-FMVCTE algorithm showed promising prognostic performance. This algorithm provides a potential method to extend the detection of advanced liver fibrosis to all chronic liver disease patients and to reduce unnecessary referrals of patients without significant fibrosis to hepatologists. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosisJournal of HepatologyVol. 66Issue 6PreviewChronic liver diseases (CLD) are very common: worldwide, an estimated 160 million people have chronic hepatitis C [1], 240 million have chronic hepatitis B [2], and 25% of the general population has non-alcoholic fatty liver disease (NAFLD) [3]. CLD can lead to a progressive accumulation of fibrosis in the liver which progressively evolves to cirrhosis and its life-threatening complications such as hepatocellular carcinoma (HCC), liver failure, variceal bleeding, or renal insufficiency. In 2012, driven by the growing worldwide burden of CLD, cirrhosis was responsible for more than 35 million years of lost life and thus became the eleventh leading cause of mortality among non-communicable diseases [4]. Full-Text PDF Reply to: “Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FMVCTE algorithm” and to “Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes”Journal of HepatologyVol. 68Issue 3PreviewScreening of advanced liver fibrosis: one step at a time Full-Text PDF

The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.

Predictive Performance of Elift for Liver Inflammation and Fibrosis in Chronic Liver Diseases

Serum CHI3L1 As a Biomarker for Non-invasive Diagnosis of Liver Fibrosis.

Pitfalls in the Non-Invasive Assessment of Liver Fibrosis with Elift-Fmvcte Algorithm

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.

Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection.

Validation of FibroTest to Diagnose Liver Fibrosis in Patients with Chronic Hepatitis B

A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels.

Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Transient Elastography Compared to Serum Markers to Predict Liver Fibrosis in a Cohort of Chinese Patients with Chronic Hepatitis B

A Novel Noninvasive Index for the Prediction of Moderate to Severe Fibrosis in Chronic Hepatitis B Patients

Serum Markers for Predicting Advanced Fibrosis in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Plateletcrit As a Potential Index for Predicting Liver Fibrosis in Chronic Hepatitis B

A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B.

Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters.

[Fibrotest-Actitest for Predicting Liver Fibrosis and Inflammatory Activity in Chinese Patients with Chronic Hepatitis B].

Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels.

Clinical Study on the Liver Stiffness Value Measured by FibroScan and Aspartate Transaminase-to-platelet Ratio Index for Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis B

A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients with Chronic Hepatitis B

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C